Folate / B9

• Periconceptional prevention of neural-tube defects
• Pregnancy planning and the first trimester
• Correcting or preventing folate-deficiency anemia
• Homocysteine-lowering protocols
• Support during methotrexate and other antifolate therapy

Folate (vitamin B9) is a water-soluble essential vitamin centrally involved in one-carbon metabolism, the network of biochemical reactions that transfers single-carbon groups (methyl, methylene, formyl, formimino) for synthesis of nucleotides, amino acids, and methylation of DNA, RNA, proteins, and phospholipids. The two functionally most important folate-dependent reactions are: (1) thymidylate synthase, which produces dTMP from dUMP for DNA synthesis, making folate essential for cell division, particularly in rapidly dividing tissues (erythropoiesis, intestinal epithelium, developing embryo); and (2) methionine synthase (also B12-dependent), which converts homocysteine to methionine using 5-methyltetrahydrofolate as methyl donor, making folate central to the methylation reactions that regulate gene expression, neurotransmitter synthesis, and phospholipid metabolism. These two roles together explain folate's diverse clinical manifestations: deficiency produces megaloblastic anemia (shared with B12 deficiency due to common DNA synthesis defect), elevated homocysteine (shared with B12), and, most catastrophically, neural tube defects when deficiency occurs during the critical 4-week embryonic window of neural tube closure. The forms of folate that matter clinically span the natural-vs-synthetic spectrum. Food folate (the natural form, polyglutamated, found in leafy greens, legumes, and other foods) requires intestinal enzymatic deconjugation to monoglutamate before absorption, producing approximately 50% bioavailability versus the synthetic forms. Folic acid (the synthetic form used in supplements and food fortification, fully oxidized pteroylmonoglutamic acid) is essentially completely absorbed but requires conversion through dihydrofolate reductase (DHFR) and methylenetetrahydrofolate reductase (MTHFR) enzymes to reach the active 5-methyltetrahydrofolate (5-MTHF) form. The methylfolate (5-MTHF, calcium L-methylfolate, sold as Metafolin and Quatrefolic) is the active circulating form that bypasses these conversion steps, the basis of the modern functional medicine emphasis on methylfolate over folic acid, particularly for individuals with MTHFR polymorphisms (C677T and A1298C) that reduce MTHFR enzyme activity. Folinic acid (5-formyltetrahydrofolate, sold as leucovorin) is the pharmaceutical rescue form used in chemotherapy contexts to bypass dihydrofolate reductase inhibition by methotrexate and other antifolate drugs. The neural tube defect prevention evidence (Wald 1991 MRC trial, Czeizel 1992 Hungarian trial, Berry 1999 China-CDC trial) established folic acid supplementation 400-800mcg daily in the preconception period as one of the highest-impact preventive nutrition interventions in modern medicine, leading to mandatory food fortification programs in the United States (1998), Canada (1998), and many other countries with substantial public health benefit.

Folate dosing has unusual public health prominence due to the critical-window pregnancy supplementation evidence. The CDC and USPSTF recommend 400-800mcg folic acid daily for all women capable of pregnancy starting 1+ months before conception and through first trimester, the most clearly evidence-supported nutrition supplementation recommendation in preventive medicine. The 400mcg dose was selected based on Wald 1991, Czeizel 1992, and Berry 1999 trials demonstrating NTD prevention at this level; higher doses (4mg) are recommended for women with previous NTD pregnancy or specific high-risk conditions. The general population RDA is 400 DFE (dietary folate equivalents)/day for adults, 600 DFE/day in pregnancy, 500 DFE/day during lactation. The DFE system accounts for the substantial bioavailability difference between food folate (~50% absorption) and synthetic folic acid (~85% absorption from supplements taken without food; ~100% from fortified foods). For methylfolate (5-MTHF) supplementation, the conversion is approximately 1mcg methylfolate ≈ 0.6-0.8mcg folic acid in pharmacological effect, though comparative clinical evidence at standard doses is limited. The Upper Limit (1000mcg/day synthetic folic acid for adults; 800mcg/day during pregnancy) reflects concern about masking B12 deficiency and the Cole 2007 colorectal adenoma signal, not acute toxicity. Take with or without food; absorption is acceptable either way. Combined B12 supplementation is reasonable to address the folic acid-masking-B12-deficiency concern, particularly in users over 50. The pharmacological context (methotrexate rescue with folinic acid, chemotherapy protocols) involves specialist coordination at higher doses.

RDA adult

400 DFE/day (dietary folate equivalents)

RDA pregnancy

600 DFE/day

RDA lactation

500 DFE/day

Preconception/pregnancy supplementation

400-800mcg folic acid

Previous NTD pregnancy / high-risk

4mg/day folic acid

Methotrexate users (RA, psoriasis, IBD)

1mg/day folic acid

Methylfolate equivalent

~1mcg methylfolate ≈ 0.6-0.8mcg folic acid

Upper Limit (synthetic)

1000mcg/day adults; 800mcg pregnancy

• Folic Acid (Synthetic Pteroylmonoglutamic Acid)

  Rating: gold

  The form used in essentially every major clinical trial (Wald 1991, Czeizel 1992, Berry 1999) and in US/Canada/many other countries' food fortification programs. Cheap, stable, well-absorbed. The form that has prevented enormous numbers of neural tube defects through population-level fortification. Conversion to active 5-MTHF requires DHFR and MTHFR enzymes, the basis of methylfolate alternative arguments in MTHFR polymorphism contexts.

• L-Methylfolate / 5-MTHF (Metafolin, Quatrefolic)

  Rating: gold

  Active circulating folate form that bypasses the conversion steps from folic acid. Branded forms include Metafolin (Merck KGaA/EMD Serono) and Quatrefolic (Gnosis/Lesaffre). Preferred in functional medicine for MTHFR polymorphism users and methylation-pathway protocols. Premium pricing but mechanistically reasonable for users with MTHFR variants or seeking active form. Clinical superiority over folic acid at standard doses in general population is debated.

• Folinic Acid (Calcium Folinate, Leucovorin)

  Rating: gold

  Pharmaceutical 5-formyltetrahydrofolate form used as rescue therapy in methotrexate chemotherapy and as alternative for users with severe MTHFR enzyme deficiency. Prescription pharmaceutical product; not typical consumer supplement form. Used in some functional medicine protocols for severe methylation issues.

• Food Folate (Polyglutamated, Natural)

  Rating: good

  The form found in leafy greens (spinach, kale, romaine), legumes (lentils, chickpeas, black beans), asparagus, broccoli, Brussels sprouts, citrus fruits, fortified grains, and liver. Bioavailability approximately 50% versus synthetic forms due to required enzymatic deconjugation. Healthy diet rich in these sources provides substantial folate; supplementation supplements rather than replaces dietary intake.

• Prenatal Vitamins (Folic Acid Standard)

  Rating: gold

  Standard prenatal vitamins include 400-800mcg folic acid as standard preconception and pregnancy supplement. The most established and broadly-evidenced supplementation use case in nutritional medicine. Higher doses (4mg/day) recommended for women with prior NTD pregnancy or specific high-risk conditions; OB-GYN coordination.

• Methylfolate Prenatal Products

  Rating: good

  Increasing prenatal supplement category using methylfolate (Metafolin or Quatrefolic) instead of folic acid. Mechanistically reasonable for users with MTHFR variants; clinical superiority over standard folic acid prenatal vitamins in general population not definitively established. Premium pricing; reasonable choice for users with MTHFR polymorphism awareness.

• B-Complex Vitamins (with Folate)

  Rating: good

  Folate is included in most B-complex formulations alongside thiamine, riboflavin, niacin, pantothenic acid, B6, biotin, and B12. Mechanistically integrated through one-carbon metabolism. Reasonable comprehensive B vitamin supplementation; the form of folate (folic acid vs methylfolate) varies across products.

• High-Dose Folic Acid (1-5mg)

  Rating: caution

  Higher-dose folic acid (1-5mg) used in specific clinical contexts: previous NTD pregnancy (4mg/day per ACOG guidance), methotrexate-induced folate deficiency, anticonvulsant-induced folate deficiency. Concerning oncology signal at chronic high doses in users with prior colorectal adenoma (Cole 2007). High-dose chronic use outside specific indication warrants reconsideration.

• Preconception and pregnancy (NTD prevention)

  Strength of evidence for this group: strong

  THE archetypal critical-window nutrition supplementation case. CDC, USPSTF, ACOG, WHO all recommend 400-800mcg folic acid daily for all women capable of pregnancy starting 1+ months before conception and through first trimester. Effect size is substantial (~50-70% NTD reduction in supplemented users). Among the highest-impact supplementation evidence in modern medicine.

• Previous NTD pregnancy or high-risk

  Strength of evidence for this group: strong

  Women with previous NTD-affected pregnancy require higher-dose folic acid (4mg/day) per ACOG guidance starting 1-3 months preconception. Also includes women on antiseizure medications, with diabetes, with obesity, and with other specific risk factors. OB-GYN coordination.

• Folate deficiency anemia

  Strength of evidence for this group: strong

  Clinical folate deficiency anemia (megaloblastic anemia of folate origin) is straightforwardly treated with folic acid supplementation. Critical to assess and treat B12 status simultaneously, folate alone in B12 deficiency masks the megaloblastic anemia while allowing neurologic damage to progress.

• Methotrexate users (rheumatoid arthritis, psoriasis, IBD, oncology)

  Strength of evidence for this group: strong

  Methotrexate inhibits dihydrofolate reductase causing iatrogenic folate deficiency. Standard practice includes folic acid 1mg/day for chronic methotrexate users (rheumatoid arthritis, psoriasis, IBD); folinic acid (leucovorin) for chemotherapy contexts. Specialist coordination for high-dose chemotherapy.

• Antiseizure medication users

  Strength of evidence for this group: modest

  Phenytoin, carbamazepine, phenobarbital, valproate, and other antiseizure medications can reduce folate status. Particularly relevant for women of reproductive age on these medications (NTD risk in pregnancy). Neurology and OB-GYN coordination for combined epilepsy + pregnancy planning.

• MTHFR polymorphism (C677T or A1298C)

  Strength of evidence for this group: cautious

  MTHFR variants reduce MTHFR enzyme activity and may affect folic acid → 5-MTHF conversion. Methylfolate supplementation theoretically bypasses this issue. Clinical relevance is debated; functional medicine emphasis often exceeds the actual outcome data. Most users with MTHFR variants do well on standard folic acid; methylfolate is reasonable preference but not essential.

• Elevated homocysteine

  Strength of evidence for this group: modest

  Folate (with B12 and B6) reduces homocysteine reliably. Whether homocysteine reduction translates to cardiovascular event reduction is contested, VITATOPS 2010 and other hard endpoint trials have been negative. Reasonable component of cardiovascular nutrition; not standalone substitute for established cardiovascular prevention.

• Heavy alcohol use disorder

  Strength of evidence for this group: modest

  Alcohol impairs folate absorption, metabolism, and utilization. Heavy drinkers commonly have folate deficiency contributing to macrocytic anemia and possibly nervous system effects. Supplementation reasonable; addressing underlying alcohol use disorder is more impactful.

• Severely restricted diets / eating disorders

  Strength of evidence for this group: modest

  Eating disorders and other severely restrictive dietary patterns can produce folate deficiency. Supplementation reasonable in specific deficient cohorts; nutritional rehabilitation and underlying eating disorder treatment more impactful.

• Hemodialysis patients

  Strength of evidence for this group: modest

  Hemodialysis removes water-soluble vitamins including folate. Routine renal-specific multivitamin (containing folate) is standard practice in dialysis patients. Nephrology coordination.

• Healthy adults with normal diet

  Strength of evidence for this group: cautious

  Most non-pregnant adults with diverse diet including leafy greens, legumes, and (in fortified-grain countries) enriched bread products achieve adequate folate intake. Routine high-dose folate supplementation in healthy adults does not provide clear benefit and carries the Cole 2007 oncologic concern at chronic high doses in users with prior adenomas.

• Vitamin B12

  Interaction: synergy

  The critical clinical pairing. Both required for methionine synthase reaction; combined deficiency produces megaloblastic anemia. Concerning clinical issue: high-dose folate can mask the megaloblastic anemia of B12 deficiency while allowing neurologic damage to progress. Modern fortification policy and combined B-complex supplements address this through routine B12 inclusion. Particularly relevant in users over 50 with potential B12 absorption issues.

• B6 (Pyridoxine)

  Interaction: synergy

  Trio with folate + B12 + B6 reduces homocysteine reliably. Whether homocysteine reduction translates to cardiovascular benefit remains contested (VITATOPS 2010 negative for stroke recurrence). Reasonable combination in cardiovascular nutrition; standard B-complex includes all three.

• Methotrexate

  Interaction: caution

  Methotrexate inhibits dihydrofolate reductase causing iatrogenic folate deficiency. Folic acid 1mg/day is standard concomitant therapy in chronic methotrexate use (RA, psoriasis, IBD), reduces GI and hematologic toxicity without compromising therapeutic effect. Folinic acid (leucovorin) is the chemotherapy-specific rescue form.

• Antiseizure Medications

  Interaction: caution

  Phenytoin, carbamazepine, phenobarbital, valproate reduce folate status. Particularly relevant for women of reproductive age on these medications. Coordinate with neurology for pregnancy planning; higher-dose folic acid (1-4mg) may be indicated.

• Trimethoprim and Sulfamethoxazole (Bactrim, Septra)

  Interaction: caution

  Trimethoprim inhibits dihydrofolate reductase (similar mechanism to methotrexate). Long-term use can produce folate deficiency. Folic acid supplementation reasonable in chronic users.

• Methylfolate in MTHFR Variants

  Interaction: synergy

  Methylfolate (5-MTHF) bypasses the MTHFR enzyme step affected by C677T and A1298C polymorphisms. Mechanistically rational; clinical outcome superiority versus folic acid at standard doses remains debated but methylfolate is reasonable preference for users with MTHFR variant awareness.

• Alcohol

  Interaction: caution

  Heavy alcohol impairs folate absorption, metabolism, and utilization. Folate supplementation reasonable in heavy drinkers; addressing alcohol use disorder more impactful.

• Previous Colorectal Adenoma

  Interaction: caution

  Cole 2007 trial demonstrated concerning signal for advanced lesion progression with 1mg/day folic acid in users with prior adenomas. Reasonable to limit chronic high-dose folic acid (>800mcg/day) in users with adenomatous polyp history. Standard prenatal levels appear safe; high-dose chronic supplementation warrants reconsideration.

• Estrogens (Combined Oral Contraceptives)

  Interaction: caution

  Oral contraceptives modestly reduce folate status; not clinically problematic for most users but worth noting in users of childbearing age (where preconception folate supplementation matters substantially).

Look for: specific folate form disclosed clearly (folic acid vs L-methylfolate vs folinic acid); explicit mcg or DFE content per serving; appropriate dose for indication (400-800mcg standard; 4mg specific clinical contexts); Metafolin or Quatrefolic ingredient identifier for clinical-grade methylfolate; combined B12 in supplementation products for users over 50; USP or NSF third-party verification; reasonable price (folic acid is genuinely inexpensive; methylfolate premium can be justified for MTHFR variant users). Avoid: proprietary "methylation" or "MTHFR" blends obscuring folate dose; high-dose chronic supplementation (>800mcg) in users with prior adenomas without specific clinical indication; products marketed primarily on MTHFR genetic testing positioning without solid evidence base; products from manufacturers without third-party testing disclosure; products substantially exceeding the Upper Limit (1000mcg adults; 800mcg pregnancy) without clinical indication.

Folate's discovery story begins with Lucy Wills, a British physician working in India in the late 1920s and early 1930s. Wills observed that pregnant Indian women, particularly those from poor backgrounds, frequently developed severe macrocytic anemia that resembled pernicious anemia but did not respond to liver extract. She systematically experimented with various nutritional approaches and identified an "antianemia factor" present in yeast and certain crude liver extracts that successfully treated the condition. Wills' factor was distinct from B12 and would eventually be identified as folate. Her work, published in the Indian Journal of Medical Research (1931), is foundational tropical hematology and prenatal nutrition. The chemical isolation came in 1941 when Herschel Mitchell and colleagues at the University of Texas isolated and characterized folic acid from spinach, naming the compound from the Latin folium (leaf) reflecting its abundance in green leafy vegetables. Synthetic folic acid production at Lederle Laboratories (1948) made the compound widely available for clinical and research use. The neural tube defect (NTD) prevention story developed across three decades. Hibbard 1965 in The Lancet first proposed the maternal folate deficiency-NTD association through observational evidence. The Smithells trials in the United Kingdom (1980-1981) provided preliminary interventional evidence. The MRC Vitamin Study (Wald and colleagues, 1991) was the foundational large randomized trial, multi-country, randomized, demonstrating 72% NTD recurrence reduction in women with prior NTD pregnancy on 4mg folic acid daily. The Czeizel and Dudás Hungarian trial (1992) extended findings to first occurrence prevention. The Berry China-CDC trial (1999) demonstrated population-scale effectiveness in high-baseline-prevalence Chinese provinces. The public health translation was substantial and rapid. The US FDA mandated folic acid fortification of enriched grain products at 140mcg per 100g grain in 1998. Canada mandated similar fortification the same year. Many other countries followed in subsequent years. The US fortification produced approximately 25-50% reduction in NTD incidence, one of the most successful nutrition public health interventions of the 20th century. The European response has been more cautious, the UK and continental European countries have generally relied on voluntary supplementation and dietary guidance rather than mandatory fortification, partly due to concerns about B12 deficiency masking and the difficulty of unfortifying after implementation. The contrast between mandatory fortification jurisdictions and voluntary supplementation jurisdictions has produced substantial public health debate. The MTHFR polymorphism era emerged in the 1990s with characterization of the C677T variant (and later A1298C) by Frosst and colleagues 1995. The variant reduces MTHFR enzyme activity affecting folic acid conversion to active 5-MTHF. Population prevalence of MTHFR variants is substantial (~10-20% homozygous C677T in some populations). The clinical implications have been the subject of substantial functional medicine emphasis, direct-to-consumer MTHFR testing produced substantial consumer awareness and methylfolate supplementation market. Mainstream genetic and clinical guidelines have remained more conservative about routine MTHFR testing and methylfolate substitution; the evidence for methylfolate clinical superiority over folic acid at standard doses in general population remains contested. The cardiovascular era saw substantial enthusiasm followed by negative trials. Elevated homocysteine was identified as cardiovascular risk marker; folate, B12, and B6 reliably reduce homocysteine. Large RCTs (VITATOPS 2010, NORVIT, HOPE-2, others) of homocysteine-lowering vitamin combinations failed to reduce hard cardiovascular endpoints despite homocysteine reduction. The story illustrates the limits of marker-targeted interventions. The Cole 2007 colorectal adenoma trial generated substantial concern about chronic high-dose folic acid in users with prior adenomas. Subsequent meta-analyses have produced mixed results; the concern about potential cancer biology effects at chronic high doses remains in clinical consciousness. The modern era continues to negotiate the tension between the well-established preconception/pregnancy folate evidence (clear public health benefit), the methylfolate functional medicine emphasis (mechanistically reasonable, clinically debated), and the chronic high-dose oncologic concerns (real but ambiguous in magnitude). Folate remains among the most consequential supplementation use cases in modern nutrition.

1. 1931Lucy Wills characterizes "antianemia factor" in pregnant Indian women
2. 1941Mitchell isolates and names folic acid from spinach
3. 1948Synthetic folic acid produced at Lederle Laboratories
4. 1965Hibbard proposes maternal folate deficiency-NTD association
5. 1980-81Smithells preliminary NTD prevention evidence (UK)
6. 1991MRC Vitamin Study (Wald), foundational NTD prevention RCT
7. 1992Czeizel and Dudás first occurrence NTD prevention
8. 1995Frosst characterizes MTHFR C677T polymorphism
9. 1998US and Canada mandate folic acid fortification of enriched grains
10. 1999Berry China-CDC large-scale population NTD prevention
11. 2007Cole colorectal adenoma signal at high dose folic acid
12. 2010VITATOPS negative for stroke recurrence prevention
13. 2010s-2020sMethylfolate functional medicine emphasis grows

• Whether methylfolate produces clinically meaningful advantages over folic acid for NTD prevention in MTHFR variant carriers, current evidence suggests folic acid adequacy in most MTHFR variant users but rigorous head-to-head trials are limited.
• Whether food fortification levels should be modified, current US 140mcg per 100g grain reflects mid-1990s evidence; some advocacy suggests higher fortification could prevent additional NTDs while critics emphasize B12-masking concerns.
• Whether the Cole 2007 colorectal adenoma signal reflects a real causal effect or chance finding, subsequent meta-analyses have produced mixed results.
• How best to address the MTHFR genetic testing market, direct-to-consumer MTHFR testing has produced substantial functional medicine practice variation; clinical guidelines remain conservative about routine MTHFR testing.
• Whether folate has applications in major depression beyond the modest Coppen 2000 antidepressant adjunct evidence.
• Whether the unmetabolized folic acid (UMFA) concern produces clinically meaningful adverse outcomes or remains primarily biochemical observation.
• How best to coordinate folate supplementation with B12 status assessment, particularly in older adults and high-risk populations.
• Whether emerging folate forms (folinic acid in consumer supplements, novel derivatives) will produce clinical evolution beyond folic acid and methylfolate.

Universally available globally as dietary supplement, food fortification, and pharmaceutical product. Legal under DSHEA in the United States and equivalent regulations globally. Not on WADA prohibited list. Folic acid fortification of enriched grain products is mandatory in the US (since 1998), Canada (since 1998), and many other countries, providing substantial population-level folate exposure independent of supplementation. Major retail brands include Nature's Bounty, NOW Foods, Thorne, Pure Encapsulations, Solgar, and most multivitamin manufacturers. Prenatal vitamin category is dominated by major pharmaceutical brands (Materna, PreNexa, OneADay, etc.) with established folic acid content. Methylfolate products from Thorne, Pure Encapsulations, Designs for Health, Seeking Health, and others command premium pricing in functional medicine markets. Prescription folinic acid (leucovorin) is widely available for pharmaceutical use. Synthetic folic acid production is well-established at commodity pricing; methylfolate production through patented processes (Metafolin from EMD Serono, Quatrefolic from Gnosis/Lesaffre) commands premium pricing.

Status current as of July 2026. Regulatory positions change, sometimes quickly.

Status

Water-soluble essential vitamin (B9)

Name origin

Latin folium (leaf), abundant in leafy greens

Endogenous synthesis

None

RDA adult

400 DFE/day

RDA pregnancy

600 DFE/day

Preconception supplementation

400-800mcg folic acid daily

What follows is unfinished work on our side, not a finding about Folate / B9. A short entry is not a safe entry.

• Cost and market. We have not documented what it sells for or who sells it.
• Supply chain. We have not mapped where it is made.
• Who uses it. We have not documented the user groups.
• What could change. No forward-looking summary yet.
• How it compares. We have not set it against the alternatives.
• Children and teenagers. We have not checked what is known about younger people.
• Where we land. We have not taken a position on this yet.